brand logo

Am Fam Physician. 2021;103(9):573-574

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial affiliations.

Key Points for Practice

• Food elimination based on allergy testing resolves esophageal inflammation in one-half of patients.

• Medication options for eosinophilic esophagitis include topical steroids delivered via an asthma inhaler and then swallowed and proton pump inhibitors.

• Dysphagia with eosinophilic esophagitis is often secondary to esophageal strictures, which can be treated with endoscopic dilation.

From the AFP Editors

Eosinophilic esophagitis is an inflammatory condition triggered by food antigens in sensitive patients. Initially characterized in the early 1990s, eosinophilic esophagitis is now recognized as a major cause of dysphagia. The evidence base of eosinophilic esophagitis is limited to short-term studies, and symptoms and endoscopic features comprising the diagnosis vary in the literature. Affected patients often have atopic diseases including asthma, allergic rhinitis, and eczema. Eosinophilic esophagitis is definitively diagnosed by eosinophilia visible in esophageal biopsies of symptomatic patients without other reasons for eosinophilia. The American Gastroenterological Association (AGA) and the Joint Task Force on Allergy-Immunology Practice Parameters (JTF) published guidelines for treatment of eosinophilic esophagitis.

Endoscopic Monitoring

Because eosinophilic esophagitis is diagnosed by biopsy, studies often define successful treatment as resolution of inflammation by reducing eosinophils to below 15 per high-power field. Symptom relief may not correspond to changes in biopsy results, and there is debate about whether endoscopy should be repeated or if treatment should be guided by symptoms. Long-term studies are needed to evaluate whether improvement in biopsy results affects patient outcomes.

Dietary Changes

Dietary changes can be effective in resolving inflammation in eosinophilic esophagitis, although studies are limited by lack of control groups and short durations.

An elemental diet, consisting of amino acid-based formulas, resolves inflammation in more than 90% of children, with less benefit in adults. However, most patients will not maintain an elemental diet because of taste, nutritional concerns, and implementation barriers, including the potential need for a gastrostomy tube. In children, elemental diets interfere with oral motor skill development and can lead to social isolation.

An empiric six-food elimination diet resolves inflammation in two-thirds of patients. Elimination diets with less restriction or food reintroduction are slightly less effective. Eliminating foods based on allergy testing results is simple and resolves inflammation in one-half of patients.


The primary treatments for eosinophilic esophagitis include proton pump inhibitors and topical steroids. Proton pump inhibitor use resolves inflammation in only one-third of patients, but this is more than double the response to placebo. Topical steroids are more effective than proton pump inhibitors, resolving inflammation in two-thirds of patients, more than four times the placebo response. In the studies reviewed, topical steroids were delivered via asthma steroid inhaler and swallowed after spraying; tablet and liquid formulations were also used. Most studies of topical steroid treatment either excluded patients with known gastroesophageal reflux disease or required previous poor response to proton pump inhibitor therapy. Studies have not shown increased adverse effects with topical steroids over placebo, although local fungal and viral infections and adrenal suppression have been reported. Oral steroid treatment demonstrates the same benefit as topical steroids, but with significant adverse effects in 40% of patients.

Other therapies have been proposed for eosinophilic esophagitis but have no evidence of benefit, including anti-interleukin-5, anti-interleukin-13, anti-interleukin-4 receptor-alpha, anti-immunoglobulin E, anti-tumor necrosis factor therapies (e.g., infliximab [Remicade]), and montelukast (Singulair) and cromolyn sodium.

Treatment of Dysphagia

Dysphagia in eosinophilic esophagitis is primarily caused by strictures secondary to inflammation. Endoscopic dilation leads to symptom improvement in 87% of patients. Most studies lacked control groups to measure the placebo response. Major complications in endoscopic dilation for eosinophilic esophagitis are similar to those performed for benign esophageal strictures, with perforation in 0.4% of patients and significant hemorrhage in 0.1%.

Guideline source: American Gastroenterological Association

Evidence rating system used? Yes

Systematic literature search described? Yes

Guideline developed by participants without relevant financial ties to industry? No

Recommendations based on patient-oriented outcomes? No

Published source: Gastroenterol. May 2020;158(6):1776–1786

Editor's Note: Eosinophilic esophagitis is now more commonly noted as source of upper gastrointestinal symptoms. A 2018 AFP editorial ( pointed out that eosinophilic esophagitis is increasingly recognized as a mimic of gastroesophageal reflux disease that fails to respond to an appropriate trial of proton pump inhibitors. A 2021 AFP article on dysphagia ( highlighted eosinophilic esophagitis as a common underlying etiology. This guideline demonstrates the limited evidence for treatment while emphasizing the few effective interventions.—Michael J. Arnold, MD, Contributing Editor

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Uniformed Services University of the Health Sciences, Department of Defense, or the U.S. government.

Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.

This series is coordinated by Michael J. Arnold, MD, contributing editor.

A collection of Practice Guidelines published in AFP is available at

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.